Two Different Tranexamic Acid Regimens in Coronary Artery Bypass Surgery

Sponsor
Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05994989
Collaborator
(none)
60
1
6.6
9.1

Study Details

Study Description

Brief Summary

The primary aim of this study is to observe the effects of two different methods of administering tranexamic acid (i.v. bolus and i.v. infusion) routinely used intraoperatively in cardiovascular surgery, on patients' postoperative bleeding amounts. According to the hypothesis established in this study, it is anticipated that administering tranexamic acid as an i.v. bolus dose followed by an 8-hour continuous infusion will result in a more stable blood level compared to the sole i.v. bolus application, thereby being more effective in influencing postoperative bleeding levels.

The study has been designed as a prospective observational research. The outcomes of two different tranexamic acid protocols applied during cardiovascular surgical procedures will be compared. The first group will consist of patients who receive a 10 mg/kg i.v. bolus of tranexamic acid after anesthesia induction, followed by an 8-hour i.v. tranexamic acid infusion at a dose of 2 mg/kg/hour. Group 2 will consist of patients who receive three doses of tranexamic acid, 10 mg/kg i.v. bolus after anesthesia induction, in the pump, and after protamine sulfate administration.

The cases collected over a period of 6 months will be divided into two groups and compared in terms of intraoperative and postoperative bleeding levels, as well as their need for blood products.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    60 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    The Effect of Two Different Tranexamic Acid Dose Regimens on Intraoperative and Postoperative Bleeding in Coronary Artery Bypass Surgery
    Anticipated Study Start Date :
    Aug 14, 2023
    Anticipated Primary Completion Date :
    Feb 14, 2024
    Anticipated Study Completion Date :
    Mar 1, 2024

    Arms and Interventions

    Arm Intervention/Treatment
    Group 1

    Patients who have undergone coronary artery bypass surgery and received intravenous tranexamic acid either as a bolus or infusion during the intraoperative period will be included in the study. The cases collected over a period of 6 months will be divided into two groups and compared. The first group will consist of patients who receive a 10 mg/kg i.v. bolus of tranexamic acid after anesthesia induction, followed by an 8-hour i.v. tranexamic acid infusion at a dose of 2 mg/kg/hour.

    Group 2

    Group 2 will consist of patients who receive three doses of tranexamic acid, 10 mg/kg i.v. bolus after anesthesia induction, in the pump, and after protamine sulfate administration.

    Outcome Measures

    Primary Outcome Measures

    1. Postoperative hemorrhage [Postoperative 1st, 6th and 24th hours]

      The amount of bleeding within the first 24 hours postoperatively will be compared.

    Secondary Outcome Measures

    1. Postoperative hemorrhage [Postoperative first 24 hours]

      The amounts of blood and blood products administered within the first 24 hours of postoperative

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients who have coronary artery disease requiring coronary artery bypass surgery with cardiopulmonary bypass and received intravenous tranexamic acid either as a bolus or infusion during the intraoperative period will be included in the study.

    • Wrriten consent obtained

    Exclusion Criteria:
    • Patients operated on for reasons other than coronary artery bypass surgery

    • Patients who operated on as emergencies

    • Patients who have preoperative liver/renal dysfunction or a history of cerebrovascular events

    • Patients under the age of 18

    • Patients who have coagulation disorder

    • Patients who have a history of allergies

    • Pregnancy or lactation

    • Disabled in spirit or law

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Diyarbakır Gazi Yaşargil Training and Research Hospital Diyarbakır Turkey

    Sponsors and Collaborators

    • Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Osman Uzundere, Principal Investigator, Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital
    ClinicalTrials.gov Identifier:
    NCT05994989
    Other Study ID Numbers:
    • 5.26.2023/408
    First Posted:
    Aug 16, 2023
    Last Update Posted:
    Aug 18, 2023
    Last Verified:
    Aug 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Osman Uzundere, Principal Investigator, Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 18, 2023